DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Rigosertib is an investigational drug.
There have been 29 clinical trials for Rigosertib. The most recent clinical trial was a Phase 3 trial, which was initiated on August 1st 2013.
The most common disease conditions in clinical trials are Preleukemia, Myelodysplastic Syndromes, and Syndrome. The leading clinical trial sponsors are Onconova Therapeutics, Inc., Bristol-Myers Squibb, and Icahn School of Medicine at Mount Sinai.
Recent Clinical Trials for Rigosertib
|Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC||Onconova Therapeutics, Inc.||Early Phase 1|
|Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC||Thomas Jefferson University||Early Phase 1|
|Rigosertib for RDEB-SCC||Prof. Johann Bauer||Phase 1/Phase 2|